Verrica Pharmaceuticals Stock Current Liabilities
| VRCA Stock | USD 0.76 0.04 5.00% |
Verrica Pharmaceuticals fundamentals help investors to digest information that contributes to Verrica Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Verrica Stock. The fundamental analysis module provides a way to measure Verrica Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Verrica Pharmaceuticals stock.
The current year's Non Current Liabilities Total is expected to grow to about 47.1 M, whereas Total Current Liabilities is forecasted to decline to about 15.5 M. Verrica | Current Liabilities |
Verrica Pharmaceuticals Company Current Liabilities Analysis
Verrica Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Verrica Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Verrica Pharmaceuticals is extremely important. It helps to project a fair market value of Verrica Stock properly, considering its historical fundamentals such as Current Liabilities. Since Verrica Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Verrica Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Verrica Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Verrica Current Liabilities Historical Pattern
Today, most investors in Verrica Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Verrica Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Verrica Pharmaceuticals current liabilities as a starting point in their analysis.
Verrica Pharmaceuticals Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Verrica Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Verrica Pharmaceuticals has a Current Liabilities of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Verrica Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Verrica Pharmaceuticals' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Verrica Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Verrica Pharmaceuticals by comparing valuation metrics of similar companies.Verrica Pharmaceuticals is currently under evaluation in current liabilities category among its peers.
Verrica Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Verrica Pharmaceuticals from analyzing Verrica Pharmaceuticals' financial statements. These drivers represent accounts that assess Verrica Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Verrica Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 395.6M | 287.7M | 247.7M | 93.9M | 331.9M | 299.0M | |
| Enterprise Value | 386.6M | 312.3M | 275.4M | 61.2M | 307.9M | 283.5M |
Verrica Fundamentals
| Return On Equity | -20.6 | ||||
| Return On Asset | -0.71 | ||||
| Operating Margin | 11.62 % | ||||
| Current Valuation | 93.06 M | ||||
| Shares Outstanding | 90.56 M | ||||
| Shares Owned By Insiders | 43.85 % | ||||
| Shares Owned By Institutions | 15.80 % | ||||
| Number Of Shares Shorted | 3.04 M | ||||
| Price To Book | 238.54 X | ||||
| Price To Sales | 7.48 X | ||||
| Revenue | 5.12 M | ||||
| Gross Profit | 8.31 M | ||||
| EBITDA | (62.2 M) | ||||
| Net Income | (67 M) | ||||
| Cash And Equivalents | 14.4 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 45.51 M | ||||
| Debt To Equity | 2.69 % | ||||
| Current Ratio | 1.25 X | ||||
| Book Value Per Share | (0.75) X | ||||
| Cash Flow From Operations | (38.58 M) | ||||
| Short Ratio | 3.19 X | ||||
| Earnings Per Share | (1.84) X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 6.33 | ||||
| Number Of Employees | 100 | ||||
| Beta | 1.46 | ||||
| Market Capitalization | 68.91 M | ||||
| Total Asset | 81.6 M | ||||
| Retained Earnings | (230.45 M) | ||||
| Working Capital | 60.51 M | ||||
| Net Asset | 81.6 M |
About Verrica Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Verrica Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verrica Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verrica Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verrica Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verrica Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verrica Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verrica Pharmaceuticals Stock:Check out Verrica Pharmaceuticals Piotroski F Score and Verrica Pharmaceuticals Altman Z Score analysis. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share 0.198 | Quarterly Revenue Growth 27.445 | Return On Assets (0.71) | Return On Equity (20.60) |
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.